The DOI matches its Crossref record; 61 of the 62 references it cites were found in a registry or an index.
Lecanemab: Appropriate Use Recommendations
Open accessAbstract
Lecanemab (Leqembi®) is approved in the United States for the treatment of Alzheimer's disease (AD) to be initiated in early AD (mild cognitive impairment [MCI] due to AD or mild AD dementia) with confirmed brain amyloid pathology. Appropriate Use Recommendations (AURs) are intended to help guide the introduction of new therapies into real-world clinical practice. Community dwelling patients with AD differ from those participating in clinical trials. Administration of lecanemab at clinical trial sites by individuals experienced with monoclonal antibody therapy also differs from the community clinic-based administration of lecanemab. These AURs use clinical trial data as well as research and care information regarding AD to help clinicians administer lecanemab with optimal safety and opportunity for effectiveness. Safety and efficacy of lecanemab are known only for patients like those participating in the phase 2 and phase 3 lecanemab trials, and these AURs adhere closely to the inclusion and exclusion criteria of the trials. Adverse events may occur with lecanemab including amyloid related imaging abnormalities (ARIA) and infusion reactions. Monitoring guidelines for these events are detailed in this AUR. Most ARIA with lecanemab is asymptomatic, but a few cases are serious or, very rarely, fatal. Microhemorrhages and rare macrohemorrhages may occur in patients receiving lecanemab. Anticoagulation increases the risk of hemorrhage, and the AUR recommends that patients requiring anticoagulants not receive lecanemab until more data regarding this interaction are available. Patients who are apolipoprotein E ε4 (APOE4) gene carriers, especially APOE4 homozygotes, are at higher risk for ARIA, and the AUR recommends APOE genotyping to better inform risk discussions with patients who are lecanemab candidates. Clinician and institutional preparedness are mandatory for use of lecanemab, and protocols for management of serious events should be developed and implemented. Communication between clinicians and therapy candidates or those on therapy is a key element of good clinical practice for the use of lecanemab. Patients and their care partners must understand the potential benefits, the potential harms, and the monitoring requirements for treatment with this agent. Culture-specific communication and building of trust between clinicians and patients are the foundation for successful use of lecanemab.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Lecanemab has a boxed warning for serious and symptomatic ARIA and requires testing for APOE ε4 prior to initiation as homozygosity increases risk.(510)”
From Dementia prevention, intervention, and care: 2024 report of the Lancet standing Commission (2024) · cites this paper as [510]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Currently, anti-amyloid monoclonal antibodies require the confirmation of amyloid-β pathology from PET or CSF before initiating therapy45,46.”
From Diagnosis of Alzheimer's disease using plasma biomarkers adjusted to clinical probability (2024) · cites this paper as [45]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“For example, although patients with early-stage AD may be candidates for anti-amyloid therapies15–17, the coexistence of pathology from other etiologies, such as VD, can increase the risk of amyloid-related imaging abnormalities18.”
From AI-based differential diagnosis of dementia etiologies on multimodal data (2024) · cites this paper as [15]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The risk of developing these potentially serious adverse effects is higher in APOEε4 carriers, particularly homozygotes, and current recommendations are that patients are genotyped for APOE before starting these therapies to offer a balanced benefit–risk discussion190.”
From Multifaceted roles of APOE in Alzheimer disease (2024) · cites this paper as [190]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Plasma biomarkers may therefore have an important role in reducing the patient burden associated with the initiation of anti-amyloid-β therapies for AD, which at present require biomarker confirmation with PET or CSF, as well as serial magnetic resonance imaging to monitor for adverse events45,46.”
From Diagnosis of Alzheimer's disease using plasma biomarkers adjusted to clinical probability (2024) · cites this paper as [45]
The cited source says what the claim attributes to it.
In the citing paper
“Individuals with two copies of the APOE‐e4 gene are at increased risk of developing ARIA.”
From 2024 Alzheimer's disease facts and figures (2024) · cites this paper as [59]
The cited source says what the claim attributes to it.
In the citing paper
“Accordingly, ApoE genotyping is now increasingly considered an important component of the pre-treatment work-up for anti-amyloid therapies [5, 8, 11, 12].”
From Plasma ApoE proteotyping for ApoE ε4 stratification in the anti-amyloid therapies era (2026) · cites this paper as [11]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Folstein, M. F., Folstein, S. E., & McHugh, P. R. (1975) · Journal of Psychiatric Research · doi:10.1016/0022-3956(75)90026-6 · Cited by 88,282
Hirono, N., Mori, E., Ikejiri, Y., Imamura, T., Shimomura, T., Hashimoto, M., Yamashita, H., & Ikeda, M. (1997) · PubMed · Cited by 21,012
Kok, J. S., Berg, I. J., & Scherder, E. J. A. (2013) · Dementia and Geriatric Cognitive Disorders Extra · doi:10.1159/000353441 · Cited by 20,589
Older Adults' Reasons for Using Technology while Aging in Place
Peek, S. T. M., Luijkx, K. G., Rijnaard, M. D., Nieboer, M. E., van der Voort, C. S., Aarts, S., van Hoof, J., Vrijhoef, H. J., & Wouters, E. (2015) · Gerontology · doi:10.1159/000430949 · Cited by 19,852
Sensitivity and False Alarm Rate of a Fall Sensor in Long-Term Fall Detection in the Elderly
Kangas, M., Korpelainen, R., Vikman, I., Nyberg, L., & Jämsä, T. J. (2014) · Gerontology · doi:10.1159/000362720 · Cited by 19,007
McKhann, G. M., Knopman, D. S., Chertkow, H., Hyman, B. T., Jack, C. R., Kawas, C. H., Klunk, W. E., Koroshetz, W. J., Manly, J. J., Mayeux, R., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.005 · Cited by 18,657
Albert, M. S., DeKosky, S. T., Dickson, D., Dubois, B., Feldman, H. H., Fox, N. C., Gamst, A., Holtzman, D. M., Jagust, W. J., Petersen, R. C., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.008 · Cited by 10,152
Self-citationLecanemab in early Alzheimer's disease
van Dyck, C. H., Swanson, C. J., Aisen, P., Bateman, R. J., Chen, C., Gee, M., Kanekiyo, M., Li, D., Reyderman, L., Cohen, S., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2212948 · Cited by 5,678
Self-citationMR signal abnormalities at 1.5 T in Alzheimer's dementia and normal aging
Fazekas, F., Chawluk, J. B., Alavi, A. A., Hurtig, H. I., & Zimmerman, R. A. (1987) · American Journal of Roentgenology · doi:10.2214/ajr.149.2.351 · Cited by 5,327
Preclinical Alzheimer’s Disease: Definition, Natural History, and Diagnostic Criteria
Dubois, B., Hampel, H., Feldman, H. H., Scheltens, P., Aisen, P., Andrieu, S., Bakardjian, H., Benali, H., Bertram, L., Blennow, K., et al. (2016) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2016.02.002 · Cited by 1,925
Self-citation
Flagged first, then by citations
1 of the 62 references couldn’t be matched to a known paper.
Research works printed but not linked: 1
- Irizarry M, van Dyck C, Sabbagh M, Bateman RJ, S. C, editors. Clarity AD: A phase 3 placebo-controlled, double-blind, parallel-group, 18-month study evaluating lecanemab in early Alzheimer's disease. 15th Clinical Trials on Alzheimer's Disease Conference; 2022; San Francisco, CA USA.
Cited by
Sorted by citations
Items 301–400 of 961
Silvaieh, S., König, T., Wurm, R., Parvizi, T., Berger–Sieczkowski, E., Goeschl, S., Hotzy, C., Wagner, M., Berutti, R., Sammler, E. M., et al. (2023) · Human Genomics · doi:10.1186/s40246-023-00499-z · Cited by 8
Lecanemab-irmb (Leqembi™) for Treatment of Alzheimer’s Disease
Gettman, L. (2024) · The Senior Care Pharmacist · doi:10.4140/tcp.n.2024.75 · Cited by 8
Greenberg, B., Lemere, C. A., Barnes, L. L., Hayden, K. M., Kukull, W. A., Oh, E. S., Snyder, P. J., Supiano, M. A., & Dilworth‐Anderson, P. (2023) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1002/trc2.12426 · Cited by 8
Yuri, T., Degrieck, R., Minczakiewicz, D., Sato, H., Kamada, J., Nakazawa, T., Vandenbroucke, I., Aoyagi, K., & Nojima, H. (2023) · Exploration of Neuroscience · doi:10.37349/en.2023.00024 · Cited by 8
Yamao, T., Miwa, K., Kaneko, Y., Takahashi, N., Miyaji, N., Hasegawa, K., Wagatsuma, K., Kamitaka, Y., Ito, H., & Matsuda, H. (2024) · Brain Sciences · doi:10.3390/brainsci14040406 · Cited by 7
Evaluating practice effects across learning trials – ceiling effects or something more?
Hammers, D. B., Bothra, S., Polsinelli, A. J., Apostolova, L. G., & Duff, K. M. (2024) · Journal of Clinical and Experimental Neuropsychology · doi:10.1080/13803395.2024.2400107 · Cited by 7
Self-citationSoria-Tobar, L., Román-Valero, L., Sebastián‐Serrano, Á., Aivar, P., Alvarez‐Castelao, B., & Dı́az-Hernández, M. (2024) · Alzheimer s Research & Therapy · doi:10.1186/s13195-024-01600-x · Cited by 8
Association of amyloid and cardiovascular risk with cognition: Findings from KBASE
Chaudhuri, S., Dempsey, D. A., Huang, Y.-N., Park, T., Cao, S., Chumin, E. J., Craft, H., Crane, P. K., Mukherjee, S., Choi, S., et al. (2024) · Alzheimer s & Dementia · doi:10.1002/alz.14290 · Cited by 7
van Gils, A. M., Tolonen, A. J., van Harten, A. C., Vigneswaran, S., Barkhof, F., Visser, L. N. C., Koikkalainen, J. R., Herukka, S., Hasselbalch, S. G., Mecocci, P., et al. (2024) · Alzheimer s Research & Therapy · doi:10.1186/s13195-024-01614-5 · Cited by 7
Aggeletaki, E., Stamos, V., Konidari, E., Εfkarpidis, A., Petrou, A., Savvopoulou, K., Kontogianni, E., Tsimpanis, K., Vorvolakos, T., Politis, A. M., et al. (2024) · Frontiers in Dementia · doi:10.3389/frdem.2024.1477242 · Cited by 7
Felbecker, A., Rouaud, O., Lathuilière, A., Allali, G., Sollberger, M. A., Meyer-Heim, T., Monsch, A. U., Lövblad, K., Becker, S., Barro-Belaygues, N., et al. (2025) · Neurodegenerative Diseases · doi:10.1159/000545799 · Cited by 7
Patient journey and decision processes for anti-amyloid therapy in Alzheimer’s disease
Mittler, B. S., Cambi, X., Biskach, M., Reisman, J. I., Wang, Y., Berlowitz, D. R., Morin, P., Miller, D. R., Brandao-Viruet, K., Clare, S. J., et al. (2025) · Journal of Neurology · doi:10.1007/s00415-025-13059-3 · Cited by 7
Mapping disparities in access to lecanemab in Georgia
Li, N.-Y., Borate, S., Zhang, K., Zuber, M., Han, Y., Chudasama, D., Correia, S., & Renzi-Hammond, L. (2025) · Alzheimer's & Dementia · doi:10.1002/alz.70100 · Cited by 8
Rodríguez, A., Calero, O., Veiga, S., Menacho-Román, M., Arribas, I., Cano, L., García-Ribas, G., & Calero, M. (2025) · Alzheimer's Research & Therapy · doi:10.1186/s13195-025-01811-w · Cited by 8
Kovacik, A. J., Vandergriff, K., Jarrett, B., & Clevenger, C. K. (2025) · Sage Open Aging · doi:10.1177/30495334251376614 · Cited by 8
Independent effects of white matter lesion volume and APOE ɛ4 on ARIA‐H in A4 Study
Shirzadi, Z., Schultz, A. P., Loghmani, N., Yang, H., Ford, J. N., Yaari, R., Properzi, M. J., Yau, W. W., Liu, L., Rafii, M. S., et al. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70751 · Cited by 6
Self-citationQi, L., Fu, Z., Tu, M., Abdullah, R., Zhao, Y., Su, X., Zhou, D., & Peng, G. (2026) · The Journal of Prevention of Alzheimer s Disease · doi:10.1016/j.tjpad.2025.100473 · Cited by 8
Mao, C., Wang, W., Huang, X., Wu, M., Wang, Y., Wang, T., Qiu, Y., Chu, S., Jin, W., Jiang, Y., et al. (2026) · Alzheimer s Research & Therapy · doi:10.1186/s13195-025-01943-z · Cited by 7
Skyles, T. J., Bouchal, S. M., Giarratana, A. O., Wengler, J., Hart, I. R., Greig, E. E., Singh, H., Huang, S. S., Martinez, F., Nguyen, B. D., et al. (2026) · Journal of Nuclear Medicine Technology · doi:10.2967/jnmt.125.271835 · Cited by 9
Agosta, F., Cecchetti, G., Spinelli, E. G., Ghirelli, A., Rugarli, G., Pisano, S., Coraglia, F., Canu, E., Castelnovo, V., Sibilla, E., et al. (2026) · Alzheimer s Research & Therapy · doi:10.1186/s13195-026-02015-6 · Cited by 7
Parent, O., Alasmar, Z., Osborne, S., Bussy, A., Costantino, M., Fouquet, J. P., Quesada, D., Pastor‐Bernier, A., Fajardo-Valdez, A., Binette, A. P., et al. (2026) · Nature Communications · doi:10.1038/s41467-026-70832-2 · Cited by 13
Advances in the drug treatment of Alzheimer’s disease: pathophysiology and mechanisms of action
Nowell, J., Crook, H., de Leon, M. J., & Edison, P. (2026) · BMJ · doi:10.1136/bmj-2023-078881 · Cited by 7
Greenberg, S. M. (2026) · New England Journal of Medicine · doi:10.1056/nejmra2411298 · Cited by 9
Self-citationAmyloid PET Quantitation and Centiloid Thresholds in the Diagnosis of Alzheimer Disease
Blazhenets, G., Soleimani‐Meigooni, D. N., Chiotis, K., Allen, I. E., Rabinovici, G. D., Joie, R. L., Meta-Centiloid Study Group, Apostolova, L. G., Asken, B. M., Bejanin, A., et al. (2026) · JAMA · doi:10.1001/jama.2026.13116 · Cited by 11
Self-citationConveying Risks of Harm in Alzheimer Disease by Amyloid Lowering
Thambisetty, M., & Howard, R. J. (2024) · JAMA · doi:10.1001/jama.2024.7548 · Cited by 7
Wu, C. Y., Zhang, Y., Howard, P., Huang, F., & Lee, R. H. (2024) · GeroScience · doi:10.1007/s11357-024-01424-5 · Cited by 8
Amyloid-lowering treatment in Alzheimer's disease
Jessen, F., Froelich, L., Hort, J., Winblad, B. G., & Fortea, J. (2024) · The Lancet · doi:10.1016/s0140-6736(24)02510-8 · Cited by 7
Alzheimer’s Disease Diagnosis and Management in the Age of Amyloid Monoclonal Antibodies
Hales, C. M. (2024) · Medical Clinics of North America · doi:10.1016/j.mcna.2024.10.003 · Cited by 7
MemScreen: A smartphone application for detection of mild cognitive impairment: A validation study
Dumurgier, J., Paquet, C., Hugon, J., Planche, V., Gaubert, S., Epelbaum, S., Bombois, S., Teichmann, M., Lévy, R., Baudouin, E., et al. (2025) · The Journal of Prevention of Alzheimer s Disease · doi:10.1016/j.tjpad.2025.100077 · Cited by 8
Lozupone, M., Dibello, V., Resta, E., Sardone, R., Castellana, F., Zupo, R., Lampignano, L., Bortone, I., Mollica, A., Berardino, G., et al. (2025) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2025.2500752 · Cited by 9
Health System Change for Alzheimer’s Disease-Modifying Therapies in Canada: Beginning the Discussion
Frank, A. R., Ismail, Z., Wilson, M., Gauthier, S. G., Verret, L., Hsiung, G. R., & BORRIE, M. J. (2023) · Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques · doi:10.1017/cjn.2023.322 · Cited by 7
Liu, L., Zhang, C. S., Zhang, A. L., Cai, Y., & Xue, C. C. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1341074 · Cited by 7
Drugs for Alzheimer’s disease: Where are we coming from? Where are we going?
Angioni, D., Delrieu, J., Coley, N., Ousset, P., Shi, J., & Vellas, B. J. (2024) · 中国科学通报：英文版 · doi:10.1016/j.scib.2024.02.021 · Cited by 7
Donnelly, P. S., Sweeney, A., Wilson, E., Passmore, A. P., McCorry, N., Boeri, M., & Kane, J. P. M. (2024) · Frontiers in Dementia · doi:10.3389/frdem.2024.1421556 · Cited by 6
MRI-free processing of tau PET images for early detection
Carlson, M. L., Smith, V., Johns, E., Young, C. B., Vossler, H. A., Ward, T. J., Harrison, T. M., Tosun, D., Hohman, T. J., Landau, S. M., et al. (2024) · Imaging Neuroscience · doi:10.1162/imag_a_00369 · Cited by 6
Idnay, B., Zhang, G., Chen, F., Ta, C., Schelke, M. W., Marder, K. S., & Weng, C. (2024) · Journal of the American Medical Informatics Association · doi:10.1093/jamia/ocae274 · Cited by 6
Menéndez‐González, M. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252212029 · Cited by 8
Anti-Amyloid Drugs for Alzheimer’s Disease: Considering the Role of Depression
Moyano, B. P., Zullo, L., Rouaud, O., Vandel, P., von Gunten, A., & Allali, G. (2024) · Neurodegenerative Diseases · doi:10.1159/000541783 · Cited by 6
Park, S. A., An, Y., Park, Y.-J., Lee, J.-Y., Jeon, H., Kim, Y. S., Lee, K., Sun, K., Lee, S. M., & Moon, S. Y. (2025) · Journal of Alzheimer s Disease · doi:10.1177/13872877251314886 · Cited by 6
Altered Clearance and Amyloid-Related Imaging Abnormalities
Cogswell, P. M., Burkett, B. J., Johnson, D. R., & Pillai, J. J. (2025) · Neuroimaging Clinics of North America · doi:10.1016/j.nic.2024.12.002 · Cited by 6
Anti‐amyloid treatments: Why we think they are worth it
Schindler, S. E., Musiek, E. S., & Morris, J. C. (2025) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1002/trc2.70055 · Cited by 6
Weber, M., Roth, H. L., Abramowitz, A., & Johnson, K. G. (2025) · American Journal of Geriatric Psychiatry · doi:10.1016/j.jagp.2025.02.007 · Cited by 6
Relationships between hypometabolism and both β‐amyloid and tau PET in corticobasal syndrome
Ghirelli, A., Goodrich, A. W., Stephens, Y. C., Graff‐Radford, J., Ali, F., Machulda, M. M., Schwarz, C. G., Senjem, M. L., Agosta, F., Filippi, M., et al. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70018 · Cited by 8
Mouse models of Anti-Aβ immunotherapies
Pikus, P., Turner, R. S., & Rebeck, G. W. (2025) · Molecular Neurodegeneration · doi:10.1186/s13024-025-00836-x · Cited by 6
Cohen, A. D., & Villemagne, V. L. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70291 · Cited by 7
Sadruddin, Z., Harris, K., Bilsborough, E., Sciba, L., Vargas, A. F., Shyer, M. N., Hinojosa, M., Colby, J., Chung, K., Farrell, C. M., et al. (2025) · Geriatric Nursing · doi:10.1016/j.gerinurse.2025.05.010 · Cited by 7
Liao, F., Calvo-Rodríguez, M., Chhaya, M., Sefrin, J. P., Charych, E. I., Mezler, M., Clausznitzer, D., McGlame, E. J., Zhao, K., Rodgers, A., et al. (2025) · Acta Neuropathologica · doi:10.1007/s00401-025-02892-5 · Cited by 7
Fujita, K., Kinoshita, F., Kuroda, Y., Sugimoto, T., Yamashita, M., Sakurai, H., Yamashiro, D., Shimizu, K., Matsumoto, N., Uchida, K., et al. (2025) · Journal of Alzheimer s Disease · doi:10.1177/13872877251372957 · Cited by 6
Xu, Y., Prat, C. S., Sense, F., van Rijn, H., & Stocco, A. (2025) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1013485 · Cited by 8
Afxenti, S., Zachariou, M., Athieniti, E., Lambrianides, A., Pantzaris, M., & Spyrou, G. M. (2025) · Journal of Translational Medicine · doi:10.1186/s12967-025-06937-x · Cited by 6
Eligibility for lecanemab and donanemab in Korea under Appropriate Use Recommendations
Jeon, S. Y., Byun, M. S., Choi, H. J., Kim, Y. H., Gwag, C. H., Oh, Y., Park, J. E., Yi, D., Jung, G., Ahn, H., et al. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70875 · Cited by 6
A ketogenic diet improves memory in females in the APOE4 mouse model of Alzheimer’s disease
Lucente, J. D., Rutkowsky, J. M., Provenzano, A. E., Persico, G., Zhou, Z., Jin, L., Ramsey, J. J., Montgomery, C. B., Kim, K., Giorgio, M., et al. (2025) · GeroScience · doi:10.1007/s11357-025-01998-8 · Cited by 9
Mangalagiu, A. G., Petrescu, B. M., Riga, S., & Vasiliu, O. (2025) · NeuroSci · doi:10.3390/neurosci7010002 · Cited by 6
FDA-Approved Passive Immunization Treatments Against Aβ in Alzheimer’s Disease: Where Are We Now?
Higgins, M. J., Wasef, V., & Kwakowsky, A. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27020883 · Cited by 7
Bellelli, F., Delrieu, J., van Kan, G. A., Peluso, A., Soriano, G., Vellas, B. J., Angioni, D., & Sourdet, S. (2026) · Alzheimer s Research & Therapy · doi:10.1186/s13195-026-01966-0 · Cited by 6
Wang, Y., Li, M., Kazis, L. E., & Xia, W. (2023) · Journal of Aging Research and Lifestyle · doi:10.14283/jarlife.2023.8 · Cited by 6
Antidepressants and the risk of bleeding in the era of anti‐amyloid drugs
Moyano, B. P., Chiabotti, P. S., Zullo, L., Rouaud, O., von Gunten, A., Girardin, F. R., & Allali, G. (2023) · Alzheimer s & Dementia · doi:10.1002/alz.13435 · Cited by 6
Wang, Y., Ren, D., Roberts, J. S., Tamres, L. K., & Lingler, J. H. (2024) · The Journal of Prevention of Alzheimer s Disease · doi:10.14283/jpad.2024.50 · Cited by 6
Feldman, S. J., Blasco, D., Mones, M., & Roberts, J. S. (2024) · The Journal of Prevention of Alzheimer s Disease · doi:10.14283/jpad.2024.69 · Cited by 6
Zhang, Y., Yu, W., Zhang, L., & Li, P. (2024) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2024.2396911 · Cited by 6
Use of biomarkers in the diagnosis of Alzheimer’s disease in adults with intellectual disability
McFeely, A., O’Connor, A., & Kennelly, S. (2024) · The Lancet Healthy Longevity · doi:10.1016/j.lanhl.2024.100639 · Cited by 6
Stögmann, E., & Schmidt, R. (2025) · Wiener klinische Wochenschrift · doi:10.1007/s00508-024-02466-7 · Cited by 6
Designing an intervention to improve cognitive evaluations in primary care
O’Brien, K. S., Harkins, K. A., Peifer, M. K., Kleid, M., Coykendall, C., Shea, J. A., Karlawish, J. H., & Burke, R. E. (2025) · Implementation Science Communications · doi:10.1186/s43058-025-00693-1 · Cited by 6
Autoradiographic comparison between [11C]PiB and [18F]AZD4694 in human brain tissue
Aliaga, A., Therriault, J., Quispialaya, K. M., Aliaga, A., Kunach, P., Macedo, A. C., Hopewell, R., Rahmouni, N., Soucy, J., Massarweh, G., et al. (2025) · EJNMMI Research · doi:10.1186/s13550-025-01216-8 · Cited by 5
Connected Speech Alterations and Progression in Patients With Primary Progressive Aphasia Variants
Canu, E., Agosta, F., Lumaca, L., Basaia, S., Castelnovo, V., Santicioli, S., Pisano, S., Gatti, E., Lamanuzzi, A., Spinelli, E. G., et al. (2025) · Neurology · doi:10.1212/wnl.0000000000213524 · Cited by 6
Gauthier, S. G., Ismail, Z., Goodarzi, Z., Ng, K. P., & Rosa‐Neto, P. (2023) · The Journal of Prevention of Alzheimer s Disease · doi:10.14283/jpad.2023.72 · Cited by 6
Sato, K., Niimi, Y., Ihara, R., Iwata, A., Ikeuchi, T., & Iwatsubo, T. (2024) · Journal of Community Genetics · doi:10.1007/s12687-024-00697-9 · Cited by 6
The Therapeutic Potential of Melatonin in Alzheimer's Disease: A Comprehensive Review
Zhang, J., Feng, M., & Kong, L. (2024) · Current Medicinal Chemistry · doi:10.2174/0109298673286807240326085736 · Cited by 6
Heed the Warning Signs to Avoid Serious ARIA
Salloway, S., Schrag, M., & Saver, J. L. (2024) · Neurology · doi:10.1212/wnl.0000000000209674 · Cited by 6
Self-citationGiaquinto, F., Lorenzini, P., Salvi, E., Carnevale, G., Vaccaro, R., Matascioli, F., Corbo, M., Locuratolo, N., Vanacore, N., Bacigalupo, I., et al. (2024) · Journal of Alzheimer s Disease · doi:10.3233/jad-240594 · Cited by 5
Pearls and Oy-sters: A Patient on Lecanemab Newly Diagnosed With Atrial Fibrillation
Ryan, D., Zwischenberger, B. A., & Liu, A. (2024) · Neurology · doi:10.1212/wnl.0000000000210125 · Cited by 5
Scaling Alzheimer's Care: The Case for Specialized Treatment Clinics
Vidoni, E. D., Parks, A. C., Brunette, A. M., Kreszyn, K., Townley, R. A., Arthur, A. K., Gillen, L., Perales‐Puchalt, J., Lewandowski, T., Mudaranthakam, D. P., et al. (2025) · Journal of the American Geriatrics Society · doi:10.1111/jgs.19461 · Cited by 5
O’Donnell, A. J., Fortunato, A. T., Spitznogle, B. L., Reddy, N. M., Kerper, S. A., & Handler, S. M. (2025) · Journal of the American Geriatrics Society · doi:10.1111/jgs.19577 · Cited by 5
Schwartz, N. U., Dietz, C. D., Araújo, I. P., Villanueva-Meyer, J. E., Chiong, W., Lane‐Donovan, C., VandeVrede, L. A., Ljubenkov, P. A., Wang, Y., Soleimani‐Meigooni, D. N., et al. (2025) · Neurology Clinical Practice · doi:10.1212/cpj.0000000000200508 · Cited by 5
Trends in FDA drug approvals: 2021–2024 insights & innovations
Raut, G., & Sharma, S. (2025) · Annales Pharmaceutiques Françaises · doi:10.1016/j.pharma.2025.06.004 · Cited by 6
Yan, J., Yang, X., Li, G., Ramírez, O. A., Hagenston, A. M., Chen, Z.-Y., & Bading, H. (2025) · Molecular Psychiatry · doi:10.1038/s41380-025-03143-5 · Cited by 6
Challenges and opportunities in nanotherapeutics targeted for central nervous system disorders
Yong, J. M., Hakobyan, K., Mahmud, S. A. Z., Johnson, D., Lee, J., Diwan, A. D., Gu, Z., Moalem‐Taylor, G., & Mao, G. (2025) · Nanoscale · doi:10.1039/d5nr02463c · Cited by 5
Musso, G., Cosma, C., Moz, S., Gabelli, C., Navaglia, F., Codemo, A., Zambon, C. F., Cagnin, A., Antonini, A., Corbetta, M., et al. (2026) · Clinica Chimica Acta · doi:10.1016/j.cca.2025.120659 · Cited by 6
Xiong, C., Tang, Y., Chen, J., Fan, M., Wei, L., Dong, Z., Lai, X., Men, X., Chen, Q., Li, D., et al. (2025) · Translational Neurodegeneration · doi:10.1186/s40035-025-00512-6 · Cited by 6
Villarejo‐Galende, A., González‐Sánchez, M., Hilario, A., Velasco, S. L., Morenas‐Rodríguez, E., Muñoz-García, M. I., Ramos‐González, A., Pérez-Martínez, D. A., & Blanco-Palmero, V. A. (2025) · Journal of Alzheimer s Disease · doi:10.1177/13872877251404505 · Cited by 5
Singh, A. S., Naqvi, A. R., & Chanu, M. T. (2026) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2026.01.050 · Cited by 7
Plasma p‐tau217 predicts PET‐based pathological staging for precision Alzheimer disease assessment
Kim, H., Lee, J. H., Chun, J., Kim, Y. J., Park, M., West, T., Kirmess, K. M., Verghese, P. B., Connell, D., Braunstein, J. B., et al. (2026) · Alzheimer s & Dementia · doi:10.1002/alz.71199 · Cited by 7
Maintaining and regaining episodic memory in Alzheimer disease: a circuit-based perspective
Düzel, E., & Kreutz, M. R. (2026) · Nature Reviews Neurology · doi:10.1038/s41582-026-01189-9 · Cited by 8
Pan-neurodegeneration proteomics reveals disease subtypes and molecular signatures
Shrestha, H. K., Sun, H., Yarbro, J. M., Lee, D., Liu, D., Wang, E., McReynolds, M. G., Zhang, N., Xie, B., Yang, S., et al. (2026) · Cell · doi:10.1016/j.cell.2026.02.026 · Cited by 11
Self-citationMerkel, J., Perneczky, R., Jessen, F., Frölich, L., Jansen, O., Peters, S., Berg, D., Schulz, J. B., & Bartsch, T. (2026) · Alzheimer s Research & Therapy · doi:10.1186/s13195-026-02022-7 · Cited by 5
Shimasaki, R., Kurihara, M., Bannai, T., Hatano, K., Suzuki, F., Tokumaru, A. M., Ishii, K., Ihara, R., & Iwata, A. (2026) · The Journal of Prevention of Alzheimer s Disease · doi:10.1016/j.tjpad.2026.100562 · Cited by 6
LoBue, C., McClintock, S. M., Chiang, H., Helphrey, J. H., Thakkar, V. J., & Hart, J. (2024) · Journal of Alzheimer s Disease · doi:10.3233/jad-240230 · Cited by 5
Shane, R. R., Kremen, S. A., Tan, Z. S., Tran, H., Tu, T. G., & Sicotte, N. L. (2024) · Neurology Clinical Practice · doi:10.1212/cpj.0000000000200361 · Cited by 5
Boustani, M. A., Doty, E. G., Garrison, L. P., Smolen, L. J., Klein, T. M., Murphy, D. R., Spargo, D. J., Belger, M. A., & Johnston, J. A. (2024) · Neurology and Therapy · doi:10.1007/s40120-024-00649-y · Cited by 6
de Moraes, R. C. M., Roth, J. R., Mao, H., Crawley, S. R., Xu, B. P., Watson, J. C., & Melkani, G. C. (2024) · Genes · doi:10.3390/genes15111376 · Cited by 6
Liu, W., Rao, X., Sun, W., Chen, X., Yu, L., Zhang, J., Chen, J., & Zheng, X. (2024) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-024-05164-0 · Cited by 6
Real-World Application of Anti–β-Amyloid Monoclonal Antibodies
Howe, M. D., Rabinovici, G. D., & Salloway, S. (2023) · Neurology · doi:10.1212/wnl.0000000000207873 · Cited by 5
Self-citationReply to: Challenges to identifying risk versus protective factors in Alzheimer’s disease
Fortea, J., Vaqué‐Alcázar, L., Pegueroles, J., Alcolea, D. A., Belbin, O., Dols‐Icardo, O., Videla, L., Gispert, J. D., Suárez‐Calvet, M., Johnson, S. C., et al. (2024) · Nature Medicine · doi:10.1038/s41591-024-03159-4 · Cited by 5
Lozupone, M., Dibello, V., Daniele, A., & Panza, F. (2025) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2025.2481847 · Cited by 5
MRI in the Clinical Management of Alzheimer’s Disease: from Early Detection To Therapy Guidance
Chiara, M., Francesca, T., Andrea, R., Domenico, S., Marco, R., Barbara, G., Marika, L., Dino, R., Rosario, P. A., Nicola, M., et al. (2025) · Current Radiology Reports · doi:10.1007/s40134-025-00435-0 · Cited by 5
APOE ε4 and Risk of Intracranial Hemorrhage in Patients With Atrial Fibrillation Taking Apixaban
Clocchiatti‐Tuozzo, S., Rivier, C. A., Renedo, D. B., Huo, S., de Havenon, A., Hawkes, M. A., Gilmore, E. J., Schwamm, L. H., Sheth, K. N., Gill, T. M., et al. (2025) · JAMA Neurology · doi:10.1001/jamaneurol.2025.0182 · Cited by 4
König, T., Silvaieh, S., Parvizi, T., Wurm, R., Goeschl, S., Uhlik, E., Farr, C. V., Berger–Sieczkowski, E., Untersteiner, H., Zimprich, A. A., et al. (2025) · Genetics in Medicine · doi:10.1016/j.gim.2025.101517 · Cited by 4
Comorbidities predict institutionalization and mortality in biomarker-confirmed alzheimer’s disease
Xia, X., Clark, A., Brogaard, N. J., Mourer, A., Areovimata, A., Eriksdotter, M., Zetterberg, H., Kern, S., Skillbäck, T. B., & Jönsson, L. (2025) · Alzheimer s Research & Therapy · doi:10.1186/s13195-025-01807-6 · Cited by 4
The Cost-Effective Price of Lecanemab for Patients with Early Alzheimer’s Disease in Sweden
Xia, X., Aye, S., Frisell, O., Aho, E., Handels, R. L. H., Li, Y., Wimo, A. B., Winblad, B. G., Eriksdotter, M., Skillbäck, T. B., et al. (2025) · PharmacoEconomics · doi:10.1007/s40273-025-01527-7 · Cited by 4
Rohatgi, S., Zhu, S., Calle, E., Ford, J. N., Kozak, B. M., Chagui, O. G., Vejdani‐Jahromi, M., Griffin, H. R., Farzaneh, H., Huang, R. Y., et al. (2025) · American Journal of Neuroradiology · doi:10.3174/ajnr.a8822 · Cited by 4
Metadata
- Authors
- Cummings, J., Apostolova, L., Rabinovici, G. D., Atri, A., Aisen, P., Greenberg, S., Hendrix, S., Selkoe, D., Weiner, M., Petersen, R. C., & Salloway, S.
- Affiliations
- Indiana University Indianapolis (US)
- University of California, San Francisco (US)
- Banner Health (US)
- University of Southern California (US)
- Harvard University (US)
- Brigham and Women's Hospital (US)
- Mayo Clinic (US)
- Brown University (US)
- Venue
- The Journal of Prevention of Alzheimer's Disease
- Publisher
- Elsevier BV
- Published
- 2023-09
- Volume
- 10
- Issue
- 3
- Pages
- 362-377
- ISSN
- 2274-5807 (ISSN-L)
- PMC
- PMC10313141
- OpenAlex
- W4360591479
- Cited by
- 961
- References
- 62
- Citations by year
- 2026: 335 · 2025: 305 · 2024: 249 · 2023: 71
- FWCI
- 170.48
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- The Journal of Prevention of Alzheimer s Disease (publishedVersion, cc-by)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion, cc-by)
- eScholarship (California Digital Library) (submittedVersion, cc-by)
- IUScholarWorks (Indiana University) (submittedVersion)
- Funders
- Foundation for the National Institutes of Health (R35AG71476, U01NS093334, P20GM109025, P30AG072959, P30 AG010133, R01AG053798, R01 AG057739)
- Alzheimer's Association (P30 AG010133)
- Alzheimer's Drug Discovery Foundation (P20GM109025)
- Eli Lilly and Company (P20GM109025)
- Biogen (P20GM109025)
- University of Southern California (P20GM109025)
- Patient-Centered Outcomes Research Institute
- Alnylam Pharmaceuticals
- BioClinica (P20GM109025)
- Sunovion
- Buck Institute for Research on Aging
- Prothena
- University of Oxford
- Eisai (P20GM109025)
- Novo Nordisk
- Shionogi
- H. Lundbeck A/S (P20GM109025)
- Grifols
- Nestec
- National Institutes of Health (RD005665)
- Genentech (P20GM109025)
- Allergan
- Avid Radiopharmaceuticals
- National Institute on Aging (AG010133, P30AG010133, U01AG057195, NIA U01 AG057195, R01AG053798, P20AG068053, NIA P30 AG010133, R01AG057739, R35AG71476, P30AG072959, P30AG072980, R35AG071476)
- National Institute of General Medical Sciences (P20GM109025)
- National Institute of Neurological Disorders and Stroke (U01NS093334)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
- Keywords
- lecanemab, Alzheimer's disease, amyloid-related imaging abnormalities, amyloid plaques, mild cognitive impairment, early Alzheimer's disease, bleeding risk, anticoagulation, infusion reactions, monoclonal antibody therapy, caregiver-patient communication, clinical preparedness
- MeSH terms
- Alzheimer Disease, Amyloid, Antibodies, Monoclonal, Humans, Apolipoprotein E4, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
